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5-fluorouracil (5-FU), an analog of pyrimidine, is one of the most effective antineoplastic agents, which shows 
remarkably enhanced inhibitory effects against a wide range of solid  tumors1–3. 5-FU restrains the proliferation 
of cancer cells by inhibiting thymidylate synthase, and incorporating its metabolites into RNA and  DNA4. None-
theless, the inappropriate oral absorption and reduced bioavailability of 5-FU frequently lead to disappointing 
clinical therapeutic  outcomes5–7. In addition, 5-FU also causes a variety of unfavorable effects including derma-
titis, mucositis, myelosuppression, nausea, vomiting, diarrhea and gastrointestinal problems. These unfavorable 
effects are mainly due to the lack of specificity towards cancer  cells8–10. Therefore, developing proper strategies to 
achieve targeted and efficient uptake of 5-FU into cancer cells is of critical importance to augment the effective-
ness, and lower the undesirable effects of 5-FU.
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In order to achieve targeted drug delivery, cell penetrating peptides (CPPs) that penetrate cell membranes via 
specific interactions with cell surface receptors have become increasingly popular for the design of an ideal drug 
delivery  system11–13. Epithelial growth factor receptor (EGFR), a transmembrane receptor, which is expressed 
abundantly in a number of tumor cells, and highly related to angiogenesis invasion and metastasis, has been 
studied intensively as a potential target for cancer  therapeutics14. CPPs that interact specifically with EGFR can 
serve as targeting ligands in the treatments of patients with EGFR-positive malignancies, for targeted delivery of 
therapeutic agents such as anticancer drugs, siRNA, and small molecules into cells overexpressing EGFR. In our 
previous study, a CPP with the amino acid sequence NRPDSAQFWLHH that interacts specifically with EGFR 
was isolated from a phage displayed peptide library via biopanning against A431 human squamous carcinoma 
 cell13. Further characterization revealed that it entered the A431 cells through clathrin-dependent  endocytosis13.
Over the past decade, delivery systems using nanoparticles, such as cationic liposomes, polymers, carbon 
nanotubes and virus-like nanoparticles (VLNPs) have been developed with the aim to improve therapeutic 
efficacies of anticancer drugs, while minimizing their undesirable side  effects15–21. Among these nanoparticles, 
VLNPs demonstrate the potential for the delivery of a broad spectrum of chemotherapeutics, owing to their 
favorable characteristics, including (1) biocompatibility and  biodegradability22, (2) homogeneity with specific 
compositions and molecular  structures23, (3) self-assembling into nanoparticles with relatively large  cavity24, (4) 
their structures, properties and functions can be tailored easily by protein engineering and recombinant DNA 
 techniques25, and (5) multivalency for chemical functionalizations or genetic  modifications26,27.
Hepatitis B VLNP comprising 180 or 240 subunits of the viral core antigen (HBcAg) has been studied inten-
sively in the development of multicomponent vaccines and drug delivery  systems28–30. A truncated HBcAg 
(tHBcAg), a mutant without the C-terminal arginine rich domain, also self-assembles into icosahedral  VLNP31–33. 
The tHBcAg VLNP is highly stable and robust, and it possesses a large surface area containing a variety of amino 
acid residues with different functional  groups28,33. Hence, various targeting ligands can be displayed easily on the 
surface of tHBcAg VLNPs to attain targeted drug delivery for cancer  therapeutics11,13,30,34,35.
In this study, a derivative of 5-FU, 5-fluorouracil-1-acetic acid (5-FA) that is less toxic than the former was 
synthesized. The 5-FA and CPP (NRPDSAQFWLHH) were conjugated on the surface of tHBcAg VLNP using 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and sulfo-N-hydroxysuccinimide (Sulfo-
NHS) (Scheme 1). The cytotoxicity of the newly developed tHBcAg VLNP harboring 5-FA and CPP was then 
compared with that of free 5-FA and 5-FU in cancer cells (A431, HT29 and HeLa cells) expressing different levels 
of  EGFR36, in which the conjugate demonstrated enhanced cytotoxicity towards the cells expressing higher level 




detect the expression of EGFR in A431, HT29 and HeLa cells, the cell lines were incubated with the rabbit 
anti-EGFR monoclonal antibody, Cetuximab (C225), followed by incubation with the goat anti-rabbit IgG con-
jugated to FITC. Figure 1a shows that A431 cells exhibited the highest green fluorescent intensity, indicating the 
highest expression level of EGFR in A431 cells. The fluorescent intensity in HT29 cells is lower as compared to 
A431 cells, while HeLa cells showed the lowest fluorescent intensity. This indicates that the expression level of 
EGFR in HT29 cells is lower than that in A431 cells, while HeLa cells expressed the lowest level of EGFR among 
the three cell lines. In order to elucidate the targeting property of CPP with the sequence NRPDSAQFWLHH 
towards EGFR, the FITC-conjugated CPP was incubated simultaneously with three types of cell lines express-
ing different levels of EGFR: A431, HT29 and HeLa. As shown in Fig. 1b, A431 cells exhibited an intense green 
fluorescence as compared with HT29 cells, while HeLa cells showed the lowest intensity of green fluorescence. 
These results indicated that the CPP internalized efficiently into A431 cells expressing the highest level of EGFR, 
followed by HT29 cells, which have intermediate amount of EGFR. The uptake of the CPP reduced drastically in 
HeLa cells, which have the lowest expression level of EGFR among these cell lines. The results demonstrated that 
the CPP is targeted towards EGFR for cell internalization.
Conjugation of CPP to tHBcAg VLNP via the nanoglue, and cellular uptake of the conjugated 
nanoparticle into A431, HT29 and HeLa cell lines.  The CPP (NRPDSAQFWLHH) was synthesized 
together with the nanoglue (SLLGRMKGA), and separated by a linker (GGG) between these two sequences. The 
resulting peptide, NRPDSAQFWLHHGGGSLLGRMKGA, was covalently cross-linked to the carboxyl group at 
the spikes of tHBcAg VLNP using Sulfo-NHS and EDC. The tHBcAg monomer shifted approximately 1 kDa on 
an SDS–polyacrylamide gel, demonstrating that the peptide was successfully cross-linked to the monomer (Sup-
plementary Fig. S1). The tHBcAg VLNP displaying the CPP (namely, CPP-tHBcAg VLNP) was then incubated 
with A431, HT29 and HeLa cells. The internalization efficiency of the CPP-tHBcAg VLNP into the three cell 
lines was examined with immunofluorescence microscopy, using the mouse anti-HBcAg monoclonal antibody 
as the primary antibody and the FITC-conjugated goat anti-mouse antibody as the secondary antibody. Figure 2 
shows that A431 cells gave rise to the highest green fluorescence signal as compared with HT29 cells, while 
HeLa cells had the lowest signal. This indicates that the internalization of CPP-tHBcAg VLNP into these cells is 
in EGFR-dependent manner. The result also demonstrated that the CPP was capable to deliver tHBcAg VLNP 
into cells expressing EGFR.
Synthesis and characterization of 5‑FA.  The conversion of 5-FU to 5-FA was performed as described 
in Sun et al.37. 5-FU reacted with α-chloroacetic acid in the presence of potassium hydroxide (KOH) and water 
at 60 °C (Scheme 2). The 5 h reaction yielded 83% of 5-FA. Nuclear magnetic resonance (NMR) spectroscopy 
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and electrospray ionization-high resolution mass spectrometry (ESI-HRMS) were used to characterize the 5-FA. 
The substituted elements and the chain carbon atoms are highlighted and numbered according to their positions 
in the 5-FA molecule to ease the analysis of NMR spectroscopy spectra. According to the 1H-NMR spectrum 
(Fig. 3a), there is a peak with δH at 13.23 ppm, which corresponds to a carboxyl group in C2′. The presence of 
two oxygen atoms at C2′ causes deshielding of the hydrogen atom, and consequently moving the signal to the 
downfield. The area under the curve (AUC) of the peak is approximately 1, showing that the peak was generated 
by one hydrogen atom. The doublet with δH at 11.93 and 11.92 ppm seems to correspond to the hydrogen atom 
bound to  N3, considering that it was created by only one hydrogen atom based on the AUC of the peak. This 
hydrogen atom is under influence of strong electronegative atoms in close proximity with it, which are the two 
oxygen atoms linked to  C2 and  C4, and caused the downfield position of the hydrogen atom. Additionally, there 
is no other hydrogen atom in the neighbourhood of this hydrogen atom according to the N + 1 rule. Another 
doublet with δH at 8.09 and 8.08 ppm also corresponds to one single hydrogen atom as predicted from the AUC. 
The chemical shift to downfield suggests the proximity to an electronegative atom. By comparing the  J3 coupling 
constant (6.7 Hz) with  J4 from the previous doublet, it can be concluded that this is larger, thus indicating a 
hydrogen or fluorine atom in position  J3. The peak with a signal of δH at 4.36 ppm, and AUC of 2 indicates that 
the signal corresponds to two hydrogen atoms. Considering the chemical shift displacement, it is reasonable to 
conclude that there is a weak electron withdrawer neighbour, or it suffers the influence of both strong electron-
withdrawing and strong electron-donating neighbours. This peak was then assigned to hydrogen atom in C1′ 
since it is influenced by both the electron-donor  N1 and  C2′ (Fig. 3a). The hydroxyl peak with δH at 13.23 ppm 
corresponds to the carboxyl group of 5-FA. Additionally, the signals of δH at 11.92 and 8.08 ppm, respectively, 
refer to the NH and CH protons in the 5-FA ring. These data are consistent with the number of atom carbon 
resonances observed in the 13C-NMR spectrum (Fig. 3b). In 13C-NMR spectrum,  C5 represents a doublet. The 
Scheme 1.  Schematic representation of dual conjugated tHBcAg VLNP for targeted drug delivery. tHBcAg 
VLNP exhibits a number of Glu, Asp and Lys residues accessible for the conjugation of drugs and cancer 
targeting moieties using EDC and sulfo-NHS. Carboxyl groups of Glu and Asp located at the spike of the dimer 
of tHBcAg VLNP were covalently linked to the primary amines of Lys residue on the nanoglue (SLLGRMKGA) 
co-synthesized with the CPP (NRPDSAQFWLHH) targeting EGFR. The two sequences are separated by a 
linker (GGG). The CPP-tHBcAg VLNP was then conjugated with 5-FA at Lys residues exposed on the surface of 
tHBcAg VLNP. The three-dimensional structure of tHBcAg dimer was prepared using  PyMOL68 (The PyMOL 
Molecular Graphics System; https ://www.pymol .org).
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Figure 1.  Analysis of EGFR expression via immunofluorescence microscopy, and internalization of CPP-
FITC into A431, HT29 and HeLa cells expressing different levels of EGFR. (a) A431, HT 29 and HeLa cells 
were incubated with the rabbit anti-EGFR monoclonal antibody for 2 h at RT, followed by incubation with the 
goat anti-rabbit IgG conjugated to FITC for 1 h at RT to detect the expression of EGFR in the three cell lines. 
A431 cells exhibited the highest fluorescent intensity followed by HT29 cells, and HeLa cells showed the lowest 
fluorescent intensity. (b) Peptide NRPDSAQFWLHH conjugated with FITC (CPP-FITC; 0.25 mM) was added 
onto A431, HT29 and HeLa cells, incubated for 16 h at 37 °C, and observed under a fluorescence microscope. 
A431 cells that express the highest level of EGFR exhibited an intense fluorescence as compared to HT29 cells, 
which have intermediate amount of EGFR. The fluorescent signal was negligible in HeLa cells, which have the 
lowest number of EGFR/cell.
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fluorine atom connected to C5 is strongly electronegative. This electronegativity in the proximity of a carbon 
atom is in the origin of the double peak at 138.55 ppm and the peak in front. This doublet was assigned to C5 
because this is a typical signal for F–C coupling, obeying the N + 1 rule and has a large coupling constant. Moreo-
ver, the molecular mass of 5-FA determined by ESI-HRMS was 189.0324 Da (m/z), which is in high agreement 
with the calculated molecular mass 189.0306 Da  (C6H5FN2O4 [M + H]+), indicating successful conversion of 
5-FU to 5-FA (Fig. 4).  
Conjugation of 5‑FA to tHBcAg VLNP and CPP‑tHBcAg VLNP.  The conjugation of 5-FA to tHBcAg 
VLNP and CPP-tHBcAg VLNP was performed via a two-step carbodiimide method using EDC and Sulfo-
NHS. The carboxyl group of 5-FA reacted with Sulfo-NHS in the presence of carbodiimide EDC to form a 
semi-stable Sulfo-NHS ester. This intermediate was then linked covalently to the primary amine  (NH2) group 
Figure 2.  Delivery of CPP-tHBcAg VLNP into A431, HT29 and HeLa cells. CPP was conjugated covalently 
to tHBcAg VLNP using EDC and sulfo-NHS. The internalization of CPP-tHBcAg VLNP was identified using 
the mouse anti-HBcAg monoclonal antibody and the FITC-conjugated goat anti-mouse antibody. A431 cells 
incubated with the CPP-tHBcAg VLNP exhibited strong green fluorescent dots as compared to HT29 and HeLa 
cells, in accordance with the EGFR expression level of the cell lines.
Scheme 2.  The conversion of 5-FU to 5-FA. 5-FU was reacted with α-chloroacetic acid in the presence of 
potassium hydroxide (KOH) and water at 60 °C for 5 h to yield 83% of 5-FA. The chemical structures were 
drawn using ChemDraw 15.0 (https ://www.perki nelme r.com/uk/categ ory/chemd raw).
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exposed on the surface of tHBcAg VLNP and CPP-tHBcAg VLNP, to form an amide bond. The nanoparticles 
conjugated with 5-FA, namely 5-FA-tHBcAg VLNP and 5-FA-CPP-tHBcAg VLNP, were purified using sucrose 
density gradient ultracentrifugation, and the absorbance at 275 nm  (A275) was measured spectrophotometrically. 
In comparison to unconjugated tHBcAg VLNP, 5-FA-tHBcAg VLNP and 5-FA-CPP-tHBcAg VLNP showed a 
remarkably higher absorbance at 275 nm, indicating that the nanoparticles were successfully conjugated with 
5-FA (Fig. 5a). The conjugation efficiency of 5-FA  (CE5FA) was 3.86 ± 0.43%, amounting to approximately 833 
5-FA molecules per tHBcAg VLNP. Transmission electron microscopic analysis of the 5-FA-tHBcAg VLNP and 
5-FA-CPP-tHBcAg VLNP revealed that the nanoparticles were intact with icosahedral shape, demonstrating 
that they were stable throughout the 5-FA conjugation process (Fig. 5b).
Figure 3.  1H-NMR and 13C-NMR spectra of 5-FA. (a) 1H-NMR spectrum of 5-FA (600 MHz, solvent DMSO). 
The horizontal axis is the chemical shifts of proton signals in part per million (ppm) and the numbers above 
the axis reflect the abundance of the individual protons. 1H NMR (600 MHz, DMSO) δ 13.23 (s, 1H), 11.92 
(d, J = 4.8 Hz, 1H), 8.08 (d, J = 6.7 Hz, 1H), 4.36 (s, 2H). (b) 13C-NMR spectrum of 5-FA (151 M Hz, solvent 
DMSO). The horizontal axis represents the energy or frequency of the radio waves absorbed by 13C atoms. 13C 
NMR (151 MHz, DMSO) δ 169.28 (s), 157.54 (s), 149.66 (s), 138.55 (s), 130.64 (s), 48.63 (s).
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Cytotoxicity  of  5‑FA  and  various  5‑FA  formulations.  3-(4,5-dimethylthiazol-2-yl)-2,5,-diphe-
nyltetrazoliumbromide (MTT) assay was performed to evaluate the cytotoxicity of 5-FA, 5-FA-tHBcAg VLNP 
and 5-FA-CPP-tHBcAg VLNP towards A431, HT29 and HeLa cells. 5-FU served as a positive control, and it had 
 IC50 values of 47.02 ± 0.65 µM, 85.37 ± 1.81 µM and 43.34 ± 2.77 µM for A431, HT29 and HeLa cells, respectively 
(Fig. 6). The  IC50 value of 5-FA in all the three cell lines could not be determined even though its concentra-
tion was increased to 1 mM, indicating that the 5-FA was significantly less toxic compared to 5-FU. After the 
conjugation of 5-FA to the nanoparticles, the  IC50 values of 5-FA-tHBcAg VLNP in A431, HT29 and HeLa cells 
were 3.26 ± 0.29 µM, 71.96 ± 1.97 µM and 36.94 ± 2.52 µM, respectively. This shows that 5-FA-tHBcAg VLNP is 
more toxic than 5-FU, and the cytotoxicity of these two compounds is not in EGFR-dependent manner as their 
inhibitory activities on HeLa cells (containing the least EGFR) are higher than those on HT29 cells (containing 
the intermediate level of EGFR). Interestingly, when CPP was conjugated to 5-FA-tHBcAg VLNP, the result-
ing formulation, 5-FA-CPP-tHBcAg VLNP, demonstrated EGFR-dependent inhibitory activities, although its 
toxicity is lower than the former. A431 cells expressing the highest number of EGFR had the lowest  IC50 value, 
21.98 ± 3.8 µM, followed by HT29 cells which showed an  IC50 value of 215.16 ± 1.89 µM. The  IC50 value of 5-FA-
CPP-tHBcAg VLNP could not be determined up to 1 mM in HeLa cells, which contain the lowest level of EGFR 
among the three cell lines (Fig. 7). The negative controls, tHBcAg VLNP and CPP-tHBcAg VLNP, were not toxic 
to the three tested cell lines. 
Apoptotic activity of 5‑FA formulations on A431 cells.  Flow cytometry was performed to study the 
induction of A431 cell apoptosis by various 5-FA formulations. FITC annexin V staining was used as a marker 
for apoptotic cell death, and 5-FU served as the reference drug. The results showed that very few cells were 
apoptotic in untreated cells, as well as cells treated with tHBcAg VLNP and 5-FA (Fig. 8). The cells treated with 
5-FU, which served as a positive control, underwent apoptosis. The percentage of early apoptosis increased 
significantly in the cells treated with 5-FA-tHBcAg VLNP, 5-FA-CPP-tHBcAg VLNP and 5-FU (Fig. 8g). Fur-
thermore, the percentage of cells at late apoptotic stage increased significantly to 68.5%, 62.3%, and 72.6%, in 
the cells treated with 5-FA-tHBcAg VLNP, 5-FA-CPP-tHBcAg VLNP and 5-FU, respectively. Overall, these data 
demonstrated that 5-FA after being conjugated to tHBcAg VLNP has an anti-proliferative effect on A431 cells 
by inducing apoptosis.
Discussion
Chemotherapy is one of the most widely used methods for cancer treatments. However, low specificities of 
chemotherapeutic agents towards cancer cells in the human body always lead to poor cancer prognosis and 
 mortality38,39. Therefore, specific delivery of chemotherapeutic drugs to cancer cells and tissues with minimal 
side effects on healthy tissues is a promising field for cancer treatments. EGFR is expressed abundantly in a broad 
spectrum of human cancers such as ovary, breast, lung, bladder, colon and skin  cancers40–42. Hence, ligands that 
interact specifically with EGFR have gained popularity. Previously, we have isolated a CPP with the amino acid 
sequence NRPDSAQFWLHH from a phage displayed peptide library via  biopanning13. The internalization of 
the CPP into A431 cells was inhibited by the anti-EGFR  antibody13. Fluorescence activated cell sorting (FACS) 
analysis on EGFR performed by Beusechem et al.36 revealed that A431 cells expressed the highest level of EGFR 
with a relative median fluorescence (RMF) value of 13.5, followed by HT29 cells (RMF: 7.3) and HeLa cells (RMF: 
3.5). This is in good agreement with our study using immunofluorescence microscopy, which demonstrated 
that the EGFR expression level was the highest in A431, followed by HT29 and HeLa cells. In the present study, 
Figure 4.  Mass spectrometric analysis of 5-FA. The molecular mass of 5-FA as determined by ESI-HRMS 
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Figure 5.  Conjugation of 5-FA and CPP onto tHBcAg VLNPs. CPP (NRPDSAQFWLHH) was co-synthesized 
with the nanoglue (SLLGRMKGA), and these two sequences were separated by a GGG-linker to produce a 
24-residue peptide (NRPDSAQFWLHHGGGSLLGRMKGA). In the presence of the zero-length cross-linker 
EDC and sulfo-NHS, the nanoglue binds specifically at the tip of tHBcAg dimer, and the primary amine 
group of the Lys residue of the nanoglue was cross-linked to the adjacent carboxyl group from either Asp or 
Glu residues located at the tip of tHBcAg dimer (Scheme 1). (a) UV–visible spectra of 5-FA, tHBcAg VLNP, 
CPP-tHBcAg VLNP, 5-FA-tHBcAg VLNP and 5-FA-CPP-tHBcAg VLNP. (b) Electron micrographs of tHBcAg 
VLNP. Nanoparticles formed by (i) tHBcAg VLNP, (ii) CPP-tHBcAg VLNP, (iii) 5-FA-tHBcAg VLNP, and 
(iv) 5-FA-CPP-tHBcAg VLNP were stained with uranyl acetate and observed under a transmission electron 
microscope. White bars indicate 40 nm.
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we have further demonstrated that the degree of CPP internalization is proportional to the amount of EGFR 
expressed on different cancer cells, with A431 showing the highest fluorescence intensity, followed by HT29 
and HeLa cells. This further justifies that the internalization of the CPP into these cell lines is EGFR-dependent.
With an aim to enhance the therapeutic efficacy while minimizing undesired side effects of chemotherapy, 
researchers have designed various types of nanoparticles for incorporation of anticancer drugs, and specific 
drug delivery. VLNPs have attained much interest in the smart drug delivery system. The advantages of VLNPs 
over synthetic nanomaterials are their stable and highly ordered structural architecture in nanosize scale, which 
enhance tumor permeability and  retention43, monodispersity and ease of  production44, and well-defined inter-
faces for functionalization. Overall, VLNPs are less toxic, more stable, and more uniform as compared to non-
viral based nanoparticles such as metal nanoparticles, liposomes and polymer  particles20,45,46. To demonstrate 
the efficiency of the CPP as a targeting moiety to deliver VLNPs into cells expressing different levels of EGFR, 
the CPP was co-synthesized with the nanoglue, and covalently linked to tHBcAg VLNP. Immuno-fluorescence 
microscopy demonstrated that tHBcAg VLNP displaying the CPP successfully delivered the nanoparticle into 
A431, HT29 and HeLa cells in EGFR-dependent manner, which paves the way for the application of the CPP to 
deliver VLNPs to cancer cells overexpressing EGFR.
As one of the most commonly prescribed anti-cancer agents, 5-FU, either alone or in combination with other 
anticancer agents, has been commonly applied for the treatments of various types of  cancers47. A variety of chemi-
cally modified 5-FU derivatives have been synthesized to enhance their antitumor  efficacy48,49, but their irregular 
oral absorption, low bioavailability and lack of specificity often result in poor clinical therapeutic  outcomes5–7. In 
order to improve the oral bioavailability, a wide variety of polymers have been synthesized for direct or indirect 
attachment of 5-FU and its  derivatives50,51. In the present study, 5-FA was introduced as a 5-FU derivative as it has 
been reported to be highly effective and less  toxic52. To synthesize 5-FA, 5-FU was reacted with chloroacetic acid 
in the presence of KOH. NMR and ESI-HRMS analyses confirmed the successful conversion of 5-FU to 5-FA. In 
order to deliver the 5-FA to cancer cells overexpressing EGFR, it was then conjugated to tHBcAg VLNP displaying 
the CPP. The conjugation was confirmed with spectrophotometer, and TEM analysis revealed that conjugation 
of 5-FA and CPP to tHBcAg VLNP has no undesired effect on the icosahedral structure of the nanoparticle.
In the present study, the cytotoxic effects of various 5-FA formulations on cells expressing different levels of 
EGFR were evaluated by MTT assay. The results clearly showed that the free 5-FA is less toxic than the reference 
drug, 5-FU. A study by Imoto et al.53 revealed that 5-FU entered Caco-2 cells by passive diffusion. The terminal 
carboxyl group in 5-FA renders the molecule charged at physiological conditions, slightly more hydrophilic and 
higher polarity than 5-FU54. As a result, 5-FA is unable to diffuse easily through the lipid core of the plasma 
 membrane55,56. These properties reduce 5-FA’s cytotoxicity towards the cells. Moreover, the methyl-carboxyl 
group at N1 in the uracil group changes the 5-FU molecule in a way that makes it no longer a direct pyrimidine 
 analog57,58. However, the cytotoxic effect of 5-FA was enhannced after being conjugated to tHBcAg VLNP, due 
to the non-specific binding and uptake of tHBcAg VLNP into the  cells59, and subsequently the nanoparticle was 
hydrolyzed to release active 5-FU in the  cells60,61. The non-specific distribution of 5-FA-tHBcAg VLNP in all the 
three cancer cell lines has become a drawback for this formulation, although the cytotoxic effect of 5-FA increased 
significantly upon conjugation onto tHBcAg VLNP. To address this problem, the CPP that targets EGFR was 
conjugated onto the 5-FA-tHBcAg VLNP. The resulting conjugate, namely 5-FA-CPP-tHBcAg VLNP displayed 
a much higher cytotoxicity in A431 cells compared to HT29 cells, followed by a very low cytotoxicity in HeLa 
cells. This EGFR-dependent manner was also observed for CPP-tHBcAg VLNP in the three cell lines (Fig. 2). 
The enhanced cytotoxicity of 5-FA-CPP-tHBcAg VLNP is believed to be caused by a specific interaction between 
the CPP displayed on the VLNP with EGFR.
5-FU induces apoptosis in cancer  cells62–64, and 5-FA is believed to kill tumor cells with a similar mechanism 
as 5-FU65. Therefore, to confirm the apoptotic activity induced by various 5-FA formulations, FITC Annexin V/
PI (propidium iodide) flow cytometry assay was performed on A431 cells to identify externalization of phos-
photidylserine (PS), a prevalent sign of apoptosis. FITC Annexin V is designed as a probe with high affinity for 
PS, for the detection of early  apoptosis66. The results showed that the percentage of total apoptotic cells was far 
more than necrotic cells in A431 cells treated with the 5-FA formulations. This indicates that the 5-FA formula-
tions markedly induced apoptosis, but to a much lesser extent, to cause necrotic cell death. Therefore, together 
with the targeting property of CPP, 5-FA-CPP-tHBcAg VLNP could be used as a therapeutic agent that induces 
apoptosis in cancer cells overexpressing EGFR.
In summary, 5-FA was successfully synthesized from 5-FU, and the former was significantly less toxic than 
the latter in A431, HT29 and HeLa cells. However, the cytotoxicity of 5-FA was greatly enhanced upon conjuga-
tion to tHBcAg VLNP. Besides, the specificity of tHBcAg VLNP increased significantly by conjugating the CPP 
that targets EGFR on the surface of the nanoparticle via the nanoglue concept. The resultant 5-FA-CPP-tHBcAg 
VLNP internalized cell lines expressing EGFR in relation to the amount of the receptor. Overall, tHBcAg VLNP 
together with the EGFR-CPP is favorable for targeted drug delivery system. Apart from the CPP and 5-FA, 
other tumor targeting moieties and chemotherapeutic drugs can conveniently be presented on the outer surface 
of tHBcAg VLNP using appropriate cross-linkers, expanding the variety of anti-cancer drugs to be delivered 
specifically to different types of cancer cells.
Materials and methods
Cell culture.  The A431 (human squamous carcinoma), HT29 (human colorectal cancer) and HeLa (cervical 
cancer) cells were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% (v/v) fetal bovine 
serum (FBS) (Sigma Aldrich, St. Louis, Missouri, USA). All cells were cultured at 37 °C in an incubator with 
humidified atmosphere and 5%  CO2.
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Figure 6.  Cytotoxicity of various 5-FA formulations as determined by MTT assay. Viability of (a) A431 (b) 
HT29, and (c) HeLa cells after being treated with 5-FU, 5-FA and 5-FA-tHBcAg VLNP. 5-FA was less cytotoxic 
to all the tested cell lines as compared to the reference drug, 5-FU. The cytotoxicity of 5-FA was significantly 
enhanced after conjugation to tHBcAg VLNP. Small graphs on the right show that tHBcAg VLNP and CPP-
tHBcAg VLNP were not toxic to the tested cells. Data are expressed as mean ± SD of triplicate measurements.
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Analysis of EGFR expression using immunofluorescence microscopy.  A431, HT29 and HeLa cells 
(2 × 105 cells/well) were grown in six-well plates containing sterile glass coverslips, and incubated at 37 °C for 
24 h. Subsequently, the medium was aspirated and the cells were washed three times with PBS (2.7 mM KCl, 
137 mM NaCl, 8.1 mM  Na2HPO4, 1.47 mM  KH2PO4; pH 7.4). Then, the cells were fixed with 3.7% (w/v) para-
formaldehyde in PBS at room temperature (RT) for 10 min. After three washes, the cells were blocked with BSA 
(0.2 mg/mL, Amresco, Ohio, USA) in PBS at RT for 1 h. Subsequently, the cells were incubated with rabbit 
anti-EGFR monoclonal antibody (10 µg/mL, Cetuximab clone C225; Merck, Billerica, Massachusetts, USA) in 
PBS containing BSA (0.2 mg/mL) for 2 h at RT. After three washes, the cells were incubated with the goat anti-
rabbit IgG conjugated to FITC [1:50 dilutions in PBS containing BSA (0.2 mg/mL); Novus Biologicals, Littleton, 
Colorado, USA] for 1 h at RT. After that, the cells were washed and stained with Hoechst 33342 prior to viewing 
under a fluorescence microscope.
Selective internalization property of CPP (NRPDSAQFWLHH) in cell lines expressing different 
levels of epithelial growth factor receptor (EGFR).  A431, HT29 and HeLa cells (2 × 105 cells/well) 
were grown in six-well plates containing sterile glass coverslips and incubated at 37 °C for 24 h. Subsequently, 
the medium was aspirated, and 0.25  mM FITC-NRPDSAQFWLHH (Mimotopes Pty Ltd, Clayton, Victoria, 
Australia) was added to the cell lines accordingly, prior to a 16 h-incubation at 37 °C in a  CO2 incubator. The 
cells were then rinsed thoroughly with PBS prior to 10 min-fixation with 3.7% (w/v) paraformaldehyde in PBS, 
followed by staining of the cell nuclei with Hoechst 33342  (Ex360nm and  Em460nm; 2 drops/mL in PBS; Life Tech-
nologies, Carlsbad, California, USA) for 10 min at 25 °C. Then, the cells were thoroughly rinsed with PBS. Cover 
slips were placed onto the glass slides containing a drop of mounting medium [0.1 M propyl gallate, 20 mM Tris–
HCl, 90% (v/v) glycerol; pH 8.5], and sealed with nail polish. The cells were then observed under a fluorescence 
microscope (Olympus X5, Olympus, Tokyo, Japan).
Conjugation  of  peptide  NRPDSAQFWLHHGGGSLLGRMKGA  to  tHBcAg VLNP,  and  cellular 
uptake of CPP‑tHBcAg VLNP into A431, HT29 and HeLa cell lines.  tHBcAg VLNP was produced 
and purified as described in Tan et al.32 and Yoon et al.67. Peptide NRPDSAQFWLHHGGGSLLGRMKGA was 
conjugated at the spike of the tHBcAg VLNP by mixing tHBcAg: peptide (1:1) in phosphate buffer (25 mM 
 NaH2PO4/Na2HPO4, pH 7) in the presence of EDC and Sulfo-NHS as described in Gan et al.13. The conjugated 
product was dialyzed against phosphate buffer (pH 7) to remove the excessive cross-linkers, and concentrated 
with VIVASPIN 6 (30  kDa cut-off polyethersulfone membrane; VIVASCIENCE, Germany) at 4500×g, 4  °C. 
The CPP-tHBcAg VLNP (250 µg/mL) was applied to A431, HT29 and HeLa cells in order to study its rate of 
internalization into these cells. The cells were incubated at 37 °C for 16 h, washed, fixed, and permeabilized with 
ice cold methanol at − 20 °C for 6 min. Then, the cells were incubated with the mouse anti-HBcAg monoclonal 
antibody [1:100 dilutions in PBS containing BSA (0.2 mg/mL); Santa Cruz Biotechnology, Dallas, Texas, USA] 
for 1 h at RT, followed by incubation with FITC-conjugated goat anti-mouse antibody (1: 100 dilutions in PBS 
containing 0.2 mg/mL BSA; BD Biosciences, San Jose, CA, USA) for another 1 h at RT. After that, the cells were 
washed and stained with Hoechst 33342 prior to viewing under a fluorescence microscope.
Synthesis and characterization of 5‑fluorouracil‑1‑acetic acid  (5‑FA).  The preparation of 5-FA 
was performed as described in Sun et al.37 with slight modifications. 5-FU (1.6 g, 12.3 mmol; Nacalai Tesque, 
Kyoto, Kyoto Prefacture, Japan) was added into a 50 mL-round-bottom flask containing 8 mL aqueous KOH 
solution (2.5 g, 44.6 mmol), stirred and heated at 80 °C for 30 min, before α-chloroacetic acid (1.2 g, 12.7 mmol; 
Sigma Aldrich, St. Louis, Missouri, USA) was added drop by drop into the reaction. The reaction mixture was 
stirred and heated at 60 °C for 5 h. The progress of the reaction was monitored using thin layer chromatography 
(TLC) (Supplementary Fig. S2). The cooled reaction mixture was then adjusted to pH 5.5 with 2 M HCl solution. 
The precipitate formed was removed, and the solution was then adjusted to pH 2.0 and kept at 4 °C for 18 h. The 
precipitate was collected as a crude product, and recrystallized with water to produce 5-FA as a white crystalline 
product.
Conjugation of 5‑FA to tHBcAg VLNP and CPP‑tHBcAg VLNP.  The conjugation of 5-FA to CPP-
tHBcAg VLNP was performed as described in Biabanikhankahdani et al.34 with some modifications. The car-
boxyl group of 5-FA was activated by dissolving 5-FA (5 mg), sulfo-NHS (20 mg) and EDC (20 mg) in sodium 
phosphate buffer (25 mM  NaH2PO4/Na2HPO4, pH 6.0; 5 mL) at RT for 8 h. After that, the pH of the solution 
was increased to 7.4 with NaOH, and the CPP-tHBcAg VLNP (3 mg) in sodium phosphate buffer was added. 
The mixture was then incubated with gently agitation at 4 °C overnight, followed by sucrose density gradient 
ultracentrifugation (8–40%; 210,000×g, for 5 h at 4 °C) as described in Tan et al.32. Simultaneously, activated 
5-FA was also added to tHBcAg VLNP, and the same conjugation procedure was applied. UV–visible measure-
ments of tHBcAg VLNP, 5-FA, 5-FA-tHBcAg VLNP, 5-FA-CPP-tHBcAg VLNP and CPP-tHBcAg VLNP were 
determined using a spectrophotometer (Jenway 7315, Staffordshire, UK). The absorbance at wavelength 275 nm, 
which corresponds to the amount of 5-FU was measured at RT. The conjugation efficiency of 5-FA  (CE5-FA) and 
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Mw represents molecular weight.
Transmission electron microscopy (TEM).  tHBcAg VLNP, 5-FA-tHBcAg VLNP, CPP-tHBcAg VLNP 
and 5-FA-CPP-tHBcAg VLNP (0.35 mg/mL; 15 µL) were absorbed onto 200-mesh carbon coated copper grids. 
Negative staining of the particles was done using freshly prepared and filtered uranyl acetate solution [2% (w/v) 
in distilled water; 15 µL] for 5 min, prior to the viewing of grids under a TEM (Hitachi H-7700, Japan).
Cytotoxicity of 5‑FA  formulations.  Cytotoxicity of free 5-FU, 5-FA, 5-FA-tHBcAg VLNP, and 5-FA-
CPP-tHBcAg VLNP was determined using the cell viability MTT assay. A431, HT29 and HeLa cells (2.0 × 104 
cells/well) were seeded in 96-well plates, and incubated for 24 h. Subsequently, the culture media were discarded, 
and the cells were added with media (100 µL) containing free 5-FU, 5-FA, 5-FA-tHBcAg VLNP and 5-FA-CPP-
tHBcAg VLNP at twofold serial dilution (0.049 µM-1000 µM), and incubated for 72 h. After the incubation, 
MTT reagent (5 mg/mL; 20 µL) prepared in PBS was pipetted into the wells and incubated for 3 h. Dimethyl 
sulfoxide (DMSO; 100 µL) was then added to the wells and incubated for 15 min to dissolve the formazan crystal 
in the viable cells.  A570 nm was measured using a microtiter plate reader (Elx800, Bio-Tek Instruments, USA). The 
cytotoxicity of tHBcAg VLNP and CPP-tHBcAg VLNP was studied as negative controls.
Determination of apoptotic activity  in A431 cells  induced by 5‑FA  formulations.  A431 cells 
(2.0 × 105 cells/well) were seeded in 6-well plates, and incubated for 24 h. The culture media were then discarded, 
and the cells were added with media (2 mL) containing free 5-FU, 5-FA, 5-FA-tHBcAg VLNP and 5-FA-CPP-
tHBcAg VLNP at equivalent concentration of 5-FU and 5-FA (125 µM), and incubated for 48 h. After incubation, 
apoptotic activity of the cells was determined using FITC Annexin V Apoptosis Detection Kit (BD Biosciences, 
San Jose, California, USA). FITC Annexin V staining was performed on the cells according to the manufacturer’s 
protocol, and the fluorescence signal was examined using a flow cytometer (BD FACS-CantoIITM, Becton Dick-










Figure 7.  Selective cytotoxicity of 5-FA-CPP-tHBcAg VLNP on A431, HT29 and Hela cells. Viability 
of A431, HT29 and HeLa cells treated with 5-FA-CPP-tHBcAg VLNP. After the conjugation of CPP 
(NRPDSAQFWLHH) to the 5-FA-tHBcAg VLNP, the cytotoxic effect of 5-FA-CPP-tHBcAg VLNP became 
selective, in which it was more cytotoxic to A431 cells as compared to HT29 and HeLa cells. The cytotoxic effect 
of 5-FA-CPP-tHBcAg VLNP in HT29 was higher compared to HeLa cells. Small graphs on the right show that 
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Statistical analysis.  Statistical analysis was performed using the SPSS program. Values of p < 0.01 are con-
sidered statistically significant.
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